Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis
Transcatheter local thrombolytic therapy in patients with acute, extended splanchnic venous thrombosis is controversial. Here we present our single-center experience with transcatheter thrombolytic therapy in these patients. All consecutive patients (n=12) with acute,extended splanchnic venous thrombosis who underwent transcatheter thrombolytic therapy in our hospital, were included in this study. Thrombolytic therapy was successful for three thrombotic events and partially successful for four thrombotic events. Two patients developed minor procedure-related bleeding (17%). Six patients (50%) developed major procedure-related bleeding, with a fatal outcome in two. Transcatheter thrombolytic therapy in patients with acute, extended splanchnic vein thrombosis is found to be associated with a high rate of procedure-related bleeding. Therefore, thrombolysis should be reserved for patients in whom the venous flow cannot be restored by using conventional anticoagulant therapy or stent placement across the thrombosed vessel segment.
|Keywords||Budd-Chiari syndrome, Portal vein thrombosis, rtPA, Thrombolytic therapy, Thrombosis (venous)|
|Persistent URL||dx.doi.org/10.1160/TH08-01-0015, hdl.handle.net/1765/75038|
|Journal||Thrombosis and Haemostasis: international journal for vascular biology and medicine|
|Note||No full text available; EUR does not subscribe to this journal|
Smalberg, J.H, Spaander, M.C.W, Jie, K.S-G, Pattynama, P.M.T, van Buuren, H.R, van den Berg, B.W, … Leebeek, F.W.G. (2008). Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thrombosis and Haemostasis: international journal for vascular biology and medicine, 100(6), 1084–1088. doi:10.1160/TH08-01-0015